Huadong Medicine Co., Ltd
000963
Κατάταξη σε μετοχές
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
Τιμή μετοχής
$3.89
Κεφαλαιοποίηση
$6.83B
Αλλαγή (1 ημέρα)
-2.22%
Αλλαγή (1 έτος)
-30.58%
Χώρα
CN
Εμπόριο Huadong Medicine Co., Ltd (000963)
Κατηγορία
Healthcare
Κέρδη για την Huadong Medicine Co., Ltd (000963)
Κέρδη τον Jun 2026 TTM: $604.11M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Huadong Medicine Co., Ltd, τα τρέχοντα κέρδη της εταιρείας είναι $604.11M. Το 2024, η εταιρεία παρουσίασε κέρδη $589.32M, αύξηση σε σχέση με των κερδών του 2023 που ήταν $489.64M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Huadong Medicine Co., Ltd από 2001 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $604.11M | 5.23% |
| 2025 | $574.08M | -2.59% |
| 2024 | $589.32M | 20.36% |
| 2023 | $489.64M | 11.43% |
| 2022 | $439.43M | -1.22% |
| 2021 | $444.87M | -15.85% |
| 2020 | $528.63M | 6.07% |
| 2019 | $498.37M | 19.34% |
| 2018 | $417.61M | 16.89% |
| 2017 | $357.26M | 31.78% |
| 2016 | $271.11M | 23.98% |
| 2015 | $218.66M | 15.48% |
| 2014 | $189.36M | 21.89% |
| 2013 | $155.35M | 23.01% |
| 2012 | $126.29M | 29.91% |
| 2011 | $97.22M | 29.50% |
| 2010 | $75.07M | -9.32% |
| 2009 | $82.78M | 100.08% |
| 2008 | $41.37M | -0.62% |
| 2007 | $41.63M | 84.19% |
| 2006 | $22.60M | 31.03% |
| 2005 | $17.25M | 50.58% |
| 2004 | $11.46M | 28.58% |
| 2003 | $8.91M | -7.36% |
| 2002 | $9.62M | -15.85% |
| 2001 | $11.43M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 192.09% |
IN
|
